GET DAILY SIGNALSWhy Is Absci Corporation (ABSI) Stock Down -10.66% Today?
Key Takeaways
- ABSI shares fell 10.66% to $10.81, down from the prior session's close of $12.10, as a sharp multi-week rally unwound.
- The decline came without any company-specific negative announcement, pointing to profit-taking rather than a fundamental setback.
- A broad risk-off move hit high-beta, development-stage biotech and AI drug discovery peers, including Recursion Pharmaceuticals and Schrödinger.
- Rising Treasury yields and valuation concerns pressured unprofitable, speculative growth names ahead of a key catalyst window.
- Traders are now focused on the company's third-quarter report on November 12 and the upcoming ABS-201 hair-loss trial readout.
- For additional context on valuation, results, and outlook, explore Price Targets, Earnings, and Forecast pages.
- To see how AI-driven strategies are positioned for moves like this, browse Trending AI Robots.
Opening Summary
Absci Corporation (ABSI), a clinical-stage biopharmaceutical company that uses generative AI to design antibody therapeutics, saw its shares fall sharply on Thursday. The stock dropped 10.66% to $10.81, down from the previous session's closing price of $12.10, as investors took profits following a blistering rally. The move, which had no single company-specific trigger, reflected a broader retreat in high-beta biotechnology and AI-driven drug discovery names after the stock had surged roughly 29% over the prior week.
Profit-Taking After a Sharp Rally
The most immediate driver behind the decline was a wave of profit-taking following an unusually strong run. ABSI had climbed from around $8.25 in mid-October to a close of $12.10 on October 29, and the stock remained up more than 200% year to date even after Thursday's slide. When a speculative, high-beta name advances that quickly with limited fundamental news to justify each leg higher, it becomes vulnerable to rapid reversals as momentum traders lock in gains. Thursday's selloff extended that dynamic, with shares giving back a meaningful portion of the week's gains.
Broader Biotech and AI Drug Discovery Selloff
The decline aligned closely with weakness across the sector. Peers in AI-powered drug discovery and development-stage biotechnology, including Recursion Pharmaceuticals, Schrödinger, and Ginkgo Bioworks, also traded lower on the day, suggesting a sector-wide risk-off tilt rather than an isolated story in ABSI. With no fresh company news, the shared selling pressure across these names indicated that investors were broadly reducing exposure to the most speculative corners of the biotech market.
Macro Pressures on High-Beta, Unprofitable Names
Rising government bond yields and a more cautious risk appetite weighed on unprofitable, high-multiple growth stocks. As a clinical-stage company generating minimal revenue while funding expensive research programs, ABSI is especially sensitive to shifts in the rate environment and investor sentiment. The recent run-up had left the stock trading well above its cash and near-term revenue base, making it an easy target for de-risking when the broader tape softened.
Market Context and Trading Activity
The move occurred against a backdrop of elevated volatility in the biotech complex, with trading activity heavier than typical as investors repositioned. The decline diverged from the broader large-cap market, underscoring that the pressure was concentrated in speculative growth and biotechnology rather than being a broad-market event. After a multi-month uptrend that lifted the shares well above their 20-day and 60-day moving averages, the pullback brought the stock closer to short-term support levels that traders will now be watching closely.
What Comes Next for ABSI
Investors' attention now turns to two catalysts. First, ABSI is scheduled to report third-quarter 2026 financial results before the market opens on November 12. Second, data from the Phase 1/2a HEADLINE trial of ABS-201, the company's AI-designed anti-prolactin receptor antibody being studied for pattern hair loss, is expected this quarter, with results intended to inform dosing for the planned Phase 2 STORYLINE trial in endometriosis. The stock's near-term direction is likely to hinge on those events. Key risks include continued macro pressure on unprofitable biotech names, the possibility of underwhelming clinical data, and the valuation sensitivity that comes with a stock that has appreciated so dramatically in a short period.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of approaches for navigating volatile names like ABSI. Explore Trending AI Robots to see which automated strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for ABSI turns positive, indicating new upward trend
ABSI saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 83 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ABSI just turned positive on October 27, 2026. Looking at past instances where ABSI's MACD turned positive, the stock continued to rise in 41 of 46 cases over the following month. The odds of a continued upward trend are 89%.
ABSI moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ABSI crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +14.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABSI advanced for three days, in 242 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 149 of 175 cases where ABSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Bearish Trend Analysis
The 10-day RSI Indicator for ABSI moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 25 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
ABSI broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ABSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.760) is normal, around the industry mean (3.154). P/E Ratio (-14.089) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (769.231) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement